European Cancer Forum 2025: Innovation, Security and Sustainability
Bristol Myers Squibb’s Opdivo-Plus-Chemotherapy Regimen for Classical Hodgkin Lymphoma Receives FDA Priority Review
10 Most Promising Cancer Drugs Not Yet Approved in 2025: Solid Tumors Edition by OncoDaily
Stephanie Weiner: U.S. Medical School Enrollment Surpasses 100,000 for the First Time
Advancing Childhood Cancer Care at the 2025 St. Jude Global Alliance Convening
HER2CLIMB-05 Trial at SABCS 2025: Tucatinib Plus HP as First-Line Maintenance in HER2-Positive Metastatic Breast Cancer
A New Invention: Nanoparticle-Based Salivary Biosensor for Early Detection of Oral Squamous Cell Carcinoma
Douglas Flora: The End of Cut, Poison and Burn - How AI is Rewriting Cancer Care
